Skanska secures US assignment from Bristol-Myers Squibb valued at USD 41 M, about SEK 435 M
Skanska’s US subsidiary, Barclay White Skanska, was awarded a contract for construction management services to build a new research and development facility for the Bristol-Myers Squibb Company, a pharmaceutical and related healthcare products company.
The contract is valued at USD 41 M, approximately SEK 435 M, and is included in the order bookings for the second quarter of 2001.
Press Release
September 7, 2001
Skanska secures US assignment from Bristol-Myers Squibb valued at USD 41 M, about SEK 435 M
Skanska's US subsidiary, Barclay White Skanska, was awarded a contract for construction management services to build a new research and development facility for the Bristol-Myers Squibb Company, a pharmaceutical and related healthcare products company.
The contract is valued at USD 41 M, approximately SEK 435 M, and is included in the order bookings for the second quarter of 2001.
The 145,000 square foot, (13,500 square meters), four-story facility in New Brunswick, New Jersey will contain process and engineering laboratories, a 150-person auditorium, and administrative offices. Architecturally, the building will feature a unique oval-shaped, multi-story entrance. Work at the site has begun and is scheduled for completion in January 2003.
Barclay White Skanska joined the Skanska USA Building organization in 2000, and concentrates primarily on construction management assignments. The Philadelphia-based company has a large number of repeat customers within the growing pharmaceutical, biotechnical, medical, healthcare and educational sectors.
____________________________________________
For further information please contact:
Jeannie Willhide, Marketing Coordinator, Barclay White Skanska, Tel: +1 267 470 1000,
e-mail:
Tor Krusell, Senior Vice President, Corporate Communications, Skanska AB, Tel: +46 8 753 87 47